PBYI PUMA BIOTECHNOLOGY, INC.

PBYI financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1401667 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 9, 2026 Data checked: Nov 10, 2026
Showing 3 of 15 annual and 0 of 63 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$145.20M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
(424) 248-6500
EIN
770683487
Headquarters
LOS ANGELES, CA
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: INNOVATIVE ACQUISITIONS CORP (2007–2011)

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
$231.83M
Net Income
$23.83M
Total Assets
$202.77M
Total Equity
$146.61M
Total Debt
-
Free Cash Flow
-
Ratios
Gross Margin
73.6%
Operating Margin
11.3%
Net Margin
10.3%
Return on Equity
16.3%
Return on Assets
11.8%
Current Ratio
3.03x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

In fiscal 2025, PUMA BIOTECHNOLOGY, INC. recorded $228.37M of revenue, net income of $31.11M, and an operating cash inflow of $41.80M. At $228.37M, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. Compared with $230.47M in fiscal 2024, revenue decreased 0.9%, a top-line contraction that reduced operating scale. On a per-share basis, diluted EPS was $0.61, which connects the reported earnings outcome with the company’s diluted share count. The per-share result recorded a 1.6% decrease from fiscal 2024 diluted EPS of $0.62. Asset turnover was 1.06x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

The first profit layer was $170.21M of gross profit, the amount available after reported direct revenue costs to absorb operating expenses. Gross margin was 74.5%, so that share of each revenue unit remained after the cost of revenue reported for the period. Operating income was $37.30M, the earnings remaining from reported operations after the company’s recognized operating cost structure. Operating margin measured 16.3%, showing the portion of revenue preserved after the full set of operating costs. The bottom-line result was net income of $31.11M, after the operating, financing, tax, and other items recognized for the period. The final earnings result represented 13.6% of revenue, connecting the absolute net income figure with the company’s top-line scale. The earnings statement records $35.78M of pretax income, the profit base against which the reported tax provision can be assessed. The pretax margin was 15.7%, relating income before taxes directly to revenue. Income tax expense totaled $4.67M, providing the reported tax component that separates pretax and after-tax earnings. The income-tax provision equaled 13.1% of pretax income, showing the tax burden absorbed by the year’s earnings.

Liquidity and Capital Structure

The company held $216.30M of assets against $85.96M of liabilities and $130.34M of equity, revealing how the asset base was financed. The near-term balance sheet paired $162.69M of current assets with $81.25M of current liabilities at the reporting date. The current ratio was 2.0x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. The company held $29.64M in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 36.5% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Borrowings totaled $22.52M, adding a fixed financing obligation alongside the company’s equity capital. The debt-to-equity relationship was 0.17x, showing how much debt the company carried for each unit of book equity. Relative to total assets, debt measured 10.4%, showing how much of the asset base was matched by borrowing. Liabilities represented 39.7% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 13.7% of total assets, showing the liquid cash component within the company’s broader resource base.

Cash Flow and Earnings Quality

Operating activities produced a cash inflow of $41.80M, giving the cash-flow counterpart to the accrual-based profit measures reported for the year. The operating-cash-flow-to-net-income relationship was 1.34x, comparing cash generated by operations with the bottom-line earnings result. The cash-flow statement records $71.00K of capital expenditures, the investment amount considered after operating cash generation. Capital spending absorbed 0.2% of operating cash flow, quantifying the share of cash from operations directed to investment. Free cash flow came to $41.73M, leaving a positive amount after capital expenditures. Free cash flow represented 18.3% of revenue, linking post-investment cash generation with the company’s operating scale. Measured against total assets, free cash flow represented 19.3%, showing the cash productivity of the company’s assets.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for PUMA BIOTECHNOLOGY, INC.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $228.37M $230.47M $235.64M
Cost of Revenue $58.16M $64.40M $62.68M
Gross Profit $170.21M $166.06M $172.96M
OPERATING EXPENSES
R&D Expense $62.07M $54.94M $50.38M
SG&A Expense $70.85M $80.16M $89.93M
Other Operating Expenses (derived) $0 $0 $0
Operating Income $37.30M $30.97M $32.64M
NON-OPERATING INCOME / EXPENSE
Interest Expense - - $13.33M
Interest Income $4.08M $4.72M $2.61M
Other Income/Expense $1.03M $862.00K $759.00K
Pretax Income $35.78M $24.10M $22.67M
Income Tax $4.67M $-6.18M $1.08M
Net Income $31.11M $30.28M $21.59M
PER SHARE & SUPPLEMENTAL
Diluted EPS $0.61 $0.62 $0.45
Diluted Shares 50.65M 49.10M 47.55M
EBITDA $48.24M $42.49M $44.16M
Depreciation & Amortization $10.94M $11.52M $11.52M
Balance Sheet
ASSETS
Cash & Equivalents $29.64M $69.22M $84.59M
Short-term Investments $67.89M $31.75M $11.35M
Accounts Receivable $53.65M $32.01M $47.84M
Inventory $5.52M $8.72M $7.08M
Other Current Assets $256.00K $91.00K $912.00K
Current Assets $162.69M $147.66M $156.19M
PP&E (Net) $187.00K $515.00K $855.00K
Intangible Assets $41.39M $51.13M $60.87M
Noncurrent Assets $53.62M $65.68M $74.34M
Total Assets $216.30M $213.33M $230.53M
LIABILITIES
Accounts Payable $5.06M $5.51M $6.89M
Short-term Debt $22.52M $45.33M $34.00M
Other Current Liabilities $142.00K $0 $513.00K
Current Liabilities $81.25M $96.11M $99.38M
Long-term Debt $0 $21.72M $65.66M
Other Noncurrent Liabilities $0 $121.00K $121.00K
Noncurrent Liabilities $4.71M $25.10M $77.70M
Total Liabilities $85.96M $121.21M $177.09M
EQUITY
Common Stock $5.00K $5.00K $5.00K
Additional Paid-in Capital $1.41B $1.41B $1.40B
Retained Earnings $-1.28B $-1.31B $-1.35B
Accumulated OCI $36.00K $6.00K $-4.00K
Total Equity $130.34M $92.13M $53.44M
Total Liabilities & Equity $216.30M $213.33M $230.53M
SUPPLEMENTAL
Total Debt $22.52M $67.05M $99.66M
Shares Outstanding 50.41M 49.11M 47.65M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $41.80M $38.92M $27.01M
Capital Expenditures $71.00K $56.00K $140.00K
Cash from Investing $-36.19M $-20.44M $-19.13M
Cash from Financing $-45.20M $-33.85M $0
Free Cash Flow $41.73M $38.86M $26.87M
Beginning Cash (CFS) $71.31M $86.68M $78.79M
Net Change in Cash $-39.58M $-15.37M $7.88M
Effect of FX on Cash - - -
Calculated Ending Cash $31.73M $71.31M $86.68M
Cash per BS $29.64M $69.22M $84.59M
Cash scope difference (CFS − BS) $2.09M $2.09M $2.09M
Cash per CFS $31.73M $71.31M $86.68M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is PUMA BIOTECHNOLOGY, INC.'s annual revenue?

PUMA BIOTECHNOLOGY, INC. reported $231.83M in revenue for trailing twelve months (ending September 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is PUMA BIOTECHNOLOGY, INC. profitable?

Yes. PUMA BIOTECHNOLOGY, INC. reported $23.83M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.